Mr. Esmat Naikyar reports

AIML SUBSIDIARY NEURALCLOUD ENTERS PILOT WITH CORNERSTONE PHYSIOTHERAPY TO DEPLOY MAXYIELD AND INSIGHT360 FOR ELITE ATHLETE CARDIAC PERFORMANCE TESTING

NeuralCloud Solutions Inc., a subsidiary of AI-ML Innovations Inc., has entered into a pilot collaboration with Cornerstone Physiotherapy, a Canadian physiotherapy group, to evaluate NeuralCloud's MaxYield signal-processing engine and Insight360 performance analytics within Cornerstone's developing elite athlete program.

Cornerstone, co-founded by physiotherapist Adam Brown, is currently conducting a limited pilot with competitive Hyrox athletes as part of a broader initiative to build an evidence-based, physiotherapist-led performance program. Hyrox is an emerging global competition format combining eight kilometres of running with eight functional workout stations, designed to challenge endurance, strength and metabolic performance.

As part of this pilot, NeuralCloud will deploy MaxYield for 1-lead ECG enhancement and automated labeling, along with Insight360-NeuralCloud's performance-oriented custom reporting layer -- to generate structured cardiac performance summaries for participating athletes. The pilot aims to assess how AI-enhanced ECG signals can support athletes in identifying training responses, fatigue markers and cardiac efficiency during high-intensity functional fitness.

Insight360 is NeuralCloud's flexible, no-code reporting and visualization platform built for the performance, wellness and consumer health markets. Designed for everyday users -- including coaches, physiotherapists, trainers and athletes -- Insight360 enables the creation of custom, drag-and-drop performance reports using modular widgets. By pairing Insight360 with MaxYield, organizations can transform raw biological signals -- including chest-strap ECG data -- into clean, structured and shareable performance insights.

"Cornerstone Physiotherapy is one of the most respected rehabilitation and performance groups in the country," said Esmat Naikyar, president of NeuralCloud and chief product officer at AI-ML. "Their early work with Hyrox athletes provides an ideal environment to validate MaxYield in human performance settings. This collaboration supports our broader strategy of extending ECG-based insights into sports science, where clarity, automation and precision can meaningfully support athlete development."

Adam Brown, Cornerstone Physiotherapy co-founder, added: "Our goal is to build an elite athlete performance program grounded in clinical expertise, objective data and real-world testing. Hyrox athletes give us a unique population to understand the demands of hybrid endurance strength competition. NeuralCloud's technology allows us to explore how ECG data -- processed cleanly and consistently -- may enhance our ability to guide training and reduce risk during high-intensity workloads."

Under the pilot framework, NeuralCloud will provide MaxYield for denoising and labelling raw ECG signals and will generate Insight360 pilot-level reports to support physiotherapist review during testing sessions. The pilot will help inform product requirements for a potential athlete-specific Insight360 module, supporting NeuralCloud's expansion into performance monitoring and human athletic optimization.

"This collaboration signals our continued progress in extending MaxYield beyond clinical and preclinical ECG interpretation," said Paul Duffy, executive chairman and chief executive officer of AI-ML. "Human performance is a natural adjacency for our technology. Working with a trusted organization like Cornerstone allows us to validate early use cases while moving thoughtfully into this new vertical."

Restricted share units (RSUs)

The company also announces the grant of three million RSUs under the company's RSU/DSU (deferred share unit) plan to an officer and employees of the company to acquire up to three million common shares of the company. The RSUs were granted effective Nov. 26, 2025, vest one year from the grant date and are subject to the terms of the plan, the applicable grant agreements and the requirements of the Canadian Securities Exchange.

About AI-ML Innovations Inc.

AI-ML Innovations is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. The company's proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights -- supporting earlier diagnosis, personalized treatment and more effective care.

We seek Safe Harbor.